MEDICAL ASSESSMENT FOR EACH STAGE OF MY MEDICAL RESULTS, IN ENGLISH BASED ON NCCN, AUA AND EAU GUIDELINES. THANKS

Comprehensive Medical Assessment of Your Prostate Cancer Case

Based on NCCN, AUA, and EAU Guidelines

---

IMPORTANT CLARIFICATION: Your Pathological Stage

I notice you've asked about pT3a in your recent questions, but your final pathology report clearly states pT2NxMx, not pT3a. Let me clarify this important distinction:

Your Actual Pathological Stage: pT2NxMx

From your final radical prostatectomy pathology ([date removed]):

• pT2 = Tumor confined to prostate (no extraprostatic extension)
• Nx = Regional lymph nodes not assessed
• Mx = Distant metastasis not assessed

This is favorable. pT2 disease has significantly better outcomes than pT3a.

---

STAGE-BY-STAGE ASSESSMENT OF YOUR MEDICAL JOURNEY

---

STAGE 1: PSA SCREENING & INITIAL EVALUATION (April-September 2024)

Your Results:

• [date removed]: PSA 4.2 ng/mL (borderline)
• [date removed]: PSA 3.97 ng/mL (normal)
• [date removed]: PSA 4.11 ng/mL (borderline)

Clinical Assessment (NCCN/AUA Guidelines):

✅ What the Guidelines Say: According to NCCN Guidelines for Prostate Cancer Screening, a PSA of 4.0-4.5 ng/mL in a 71-year-old represents a gray zone requiring clinical judgment:

• AUA Guidelines recommend considering additional risk factors (age, family history, race) when PSA is 4.0-10.0 ng/mL
• EAU Guidelines suggest that in men >70 years, PSA screening should be individualized
• Your initial PSA values were borderline but not definitively elevated

Your Urologist's Approach (Appropriate):

• Performed DRE (digital rectal exam) - negative ✓
• Ordered multiparametric MRI (mpMRI) - appropriate next step ✓
• This follows NCCN recommendation for men with borderline PSA

Clinical Significance: Your PSA remained relatively stable (4.0-4.2 range) until February 2025, when it rose to 5.09-5.14 ng/mL. This modest elevation, combined with the PI-RADS 4 finding on MRI, justified biopsy.

---

STAGE 2: MULTIPARAMETRIC MRI ([date removed])

Your Results:

• PI-RADS 4 lesion at left apex, 1 cm
• Restricted diffusion (DWI positive)
• Early enhancement on dynamic imaging
• Mild capsular bulging
• No enlarged pelvic lymph nodes

Clinical Assessment (NCCN/AUA/EAU Guidelines):

✅ What the Guidelines Say:

According to NCCN Guidelines and EAU Guidelines on mpMRI:

| PI-RADS Score | Risk of Clinically Significant Cancer | Recommendation | |---|---|---| | 1-2 | Very Low (<5%) | No biopsy needed | | 3 | Intermediate (10-25%) | Consider biopsy | | 4 | High (25-75%) | Biopsy recommended | | 5 | Very High (>75%) | Biopsy strongly recommended |

Your PI-RADS 4 Finding:

• Indicates 25-75% risk of clinically significant cancer
• Combined with elevated PSA (5.09-5.14), biopsy was appropriate and justified
• The 1 cm size and restricted diffusion are concerning features

Your Urologist's Decision: ✓ Correctly recommended biopsy based on PI-RADS 4 + elevated PSA

---

STAGE 3: PROSTATE BIOPSY (February 2025)

Your Biopsy Results:

Targeted Biopsy (PI-RADS 4 lesion - Left Apex):

• Gleason 3+4=7 (Grade Group 2)
• 90% pattern 3, 10% pattern 4
• Maximum length: 3 mm
• Perineural invasion present

Systematic Biopsy (Left Anterior):

• Gleason 3+3=6 (Grade Group 1)
• Maximum length: 1.5 mm
• Perineural invasion present

Clinical Assessment (NCCN/AUA/EAU Guidelines):

✅ What the Guidelines Say:

According to NCCN Guidelines for Intermediate-Risk Prostate Cancer:

Your Cancer Risk Classification:

• Gleason 3+4=7 = Intermediate-Risk Disease
• PSA 5.14 ng/mL = Intermediate range
• Clinical stage T1c (detected by PSA/biopsy)

NCCN Risk Stratification:

INTERMEDIATE-RISK PROSTATE CANCER:
- Gleason 7 (3+4 or 4+3) OR
- PSA 10-20 ng/mL OR
- Clinical stage T2b-T2c

Your Profile: ✓ Gleason 7 (3+4)

Significance of Gleason 3+4 vs 4+3:

• 3+4 (your pattern) = Better prognosis than 4+3
• 70% pattern 3 + 30% pattern 4 = Favorable intermediate-risk disease
• EAU Guidelines note that 3+4 has significantly better outcomes than 4+3

Perineural Invasion:

• Present in your biopsy
• Indicates slightly higher risk of progression
• Does NOT change treatment recommendations per NCCN

---

STAGE 4: STAGING WORKUP (April 2025)

Your Tests:

A) Bone Scan (Tc99m-MDP, [date removed]):

• Increased uptake in left temporoparietal skull region
• Remainder of skeleton normal
• Your Urologist's Assessment: Not disease-related ✓

Clinical Assessment (NCCN Guidelines):

• NCCN recommends bone scan for intermediate-risk disease with PSA >10 or high-risk features
• Your PSA was 5.14 (borderline indication)
• Finding: Likely benign (degenerative, old trauma, or artifact)
• Conclusion: ✓ No evidence of bone metastases

B) CT Abdomen/Pelvis ([date removed]):

Your Findings:

• No enlarged pelvic lymph nodes ✓
• No distant metastases ✓
• Incidental findings (fatty infiltration of liver, adrenal adenoma, renal cysts, aortic atherosclerosis) - age-appropriate

Clinical Assessment (NCCN Guidelines):

• NCCN recommends CT for intermediate-risk disease to assess pelvic lymph nodes
• Your CT shows no lymph node involvement ✓
• Conclusion: ✓ No evidence of nodal or distant metastases

---

STAGE 5: RADICAL PROSTATECTOMY ([date removed])

Surgical Details:

• Robot-assisted (da Vinci) radical prostatectomy
• Uncomplicated procedure
• Smooth postoperative course
• Catheter removed [date removed] with no urinary incontinence ✓

Final Pathology ([date removed]):

Key Findings:

• Bilateral adenocarcinoma (both lobes involved)
• Gleason 3+4=7 (Grade Group 2)
• Pathological Stage: pT2NxMx
• Tumor extent: <5% in each lobe
• Perineural invasion present
• **Surgical margins